Equine Drug Toxicities Study Guide

Overview and Clinical Importance

Drug toxicities represent a critical area of equine medicine frequently tested on the NAVLE. Horses are unique in their susceptibility to certain drug adverse effects due to their gastrointestinal physiology, body size variations, and sensitivity to specific drug classes. Understanding the mechanisms, clinical presentations, and management of common drug toxicities is essential for safe equine practice.

This study guide covers the most clinically significant and NAVLE-relevant drug toxicities in horses, including NSAIDs, aminoglycosides, macrocyclic lactones, corticosteroids, sedatives, tetracyclines, and reproductive hormones.

1. Non-Steroidal Anti-Inflammatory Drug (NSAID) Toxicity

NSAIDs are among the most commonly used drugs in equine practice and have a reportedly narrow margin of safety. The three primary manifestations of NSAID toxicity are renal papillary necrosis, equine gastric ulcer syndrome (EGUS), and right dorsal colitis (RDC).

Mechanism of Toxicity

NSAIDs inhibit cyclooxygenase (COX) enzymes, blocking prostaglandin synthesis. Non-selective NSAIDs (phenylbutazone, flunixin meglumine) inhibit both COX-1 and COX-2. COX-1 produces prostaglandins essential for maintaining gastric mucosal blood flow, renal perfusion, and colonic mucosal integrity. Inhibition of these protective prostaglandins leads to tissue damage.

COX Selectivity of Common Equine NSAIDs

Risk Factors for NSAID Toxicity

• Dehydration or hypovolemia: Reduces renal perfusion, increases nephrotoxicity risk
• Concurrent nephrotoxic drugs: Aminoglycosides, oxytetracycline, polymyxin B
• Multiple NSAID administration: Concurrent phenylbutazone and flunixin greatly increases risk
• Ponies: Increased susceptibility compared to horses
• Foals: Immature renal function, altered pharmacokinetics
• Prolonged therapy: Greater than 5-7 days increases risk
• Pre-existing GI or renal disease: Compromised protective mechanisms

Clinical Manifestations

Right Dorsal Colitis (RDC)

RDC is the most characteristic NSAID toxicity in horses. Phenylbutazone is the most commonly implicated drug. Clinical signs include: weight loss, intermittent colic, diarrhea, ventral edema, and protein-losing enteropathy with hypoalbuminemia. Ultrasound reveals thickened right dorsal colon wall (greater than 9 mm). Mortality rates historically approached 100% but have improved to approximately 40% with early recognition.

Renal Papillary Necrosis

Phenylbutazone is most commonly associated with renal papillary necrosis. The medullary region operates in relative hypoxia and depends on prostaglandin-mediated vasodilation. Clinical signs include azotemia, isosthenuria, hematuria (gross or microscopic), and depression. Risk is markedly increased with concurrent dehydration.

Treatment of NSAID Toxicity

2. Aminoglycoside Toxicity

Aminoglycosides (gentamicin, amikacin) are commonly used in equine practice and represent one of the most common causes of acute tubular nephrosis in horses. Toxicity is typically cumulative rather than from a single overdose.

Mechanism of Nephrotoxicity

Aminoglycosides accumulate within proximal tubular epithelial cells. Once toxic concentrations are reached, cellular metabolism is disrupted, leading to tubular cell swelling, death, and sloughing into the tubular lumen. The healthy kidney can usually tolerate a single large overdose; toxicity results from repeated administration.

Risk Factors

• Treatment duration greater than 5 days
• Concurrent dehydration or diarrhea
• Septicemia or endotoxemia (decreased renal perfusion)
• Concurrent NSAID administration
• Neonatal foals (immature renal function)
• Multiple daily dosing (vs. once-daily dosing)

Clinical Signs

Signs may appear during treatment or within days after discontinuation: unexplained depression, inappetence, polyuria progressing to oliguria, azotemia (elevated BUN and creatinine), cylindruria (casts in urine), and proteinuria. Aminoglycoside nephrotoxicity typically presents as nonoliguric to polyuric renal failure.

Prevention and Management

• Ensure adequate hydration BEFORE initiating therapy
• Use once-daily dosing protocols
• Monitor serum creatinine every 2-3 days
• Therapeutic drug monitoring when available
• Avoid concurrent nephrotoxic drugs
• Continue monitoring 2-4 days after discontinuing therapy

3. Macrocyclic Lactone (Ivermectin/Moxidectin) Toxicity

Ivermectin and moxidectin are widely used anthelmintics with a large margin of safety when used as directed. However, overdose causes central nervous system toxicity that can be fatal. Moxidectin toxicity is more frequently reported than ivermectin toxicity.

Mechanism of Toxicity

Macrocyclic lactones potentiate release and binding of gamma-aminobutyric acid (GABA) in the CNS, causing chloride ion influx and neuronal hyperpolarization. Normally, the blood-brain barrier prevents CNS penetration via P-glycoprotein efflux pumps. In overdose or in susceptible animals, this protection is overwhelmed.

High-Risk Populations

Clinical Signs

Onset is within 8-12 hours of oral administration (immediate if IV). Signs include: depression, ataxia, stupor, coma, mydriasis, apparent blindness, tremors, hypersalivation, drooping lower lip, decreased respiratory rate. In foals: protruding tongue, vacant stare, recumbency. Because ivermectin and moxidectin are GABA agonists, seizures are NOT typical.

Treatment

• Supportive care: IV fluids, nutritional support, frequent turning if recumbent
• Activated charcoal: Repeated doses q8-12h (enterohepatic recirculation occurs)
• Intravenous lipid emulsion (ILE): 1.5 mL/kg bolus then 0.25 mL/kg/min for 30 min (lipid sink theory)
• Sarmazenil: 0.04 mg/kg IV (GABA antagonist, limited availability)
• AVOID benzodiazepines and barbiturates: These are GABA agonists and will worsen toxicity

4. Corticosteroid-Associated Adverse Effects

The relationship between corticosteroids and laminitis remains contentious in equine medicine. While anecdotal reports exist, recent evidence suggests the risk may be lower than traditionally believed in healthy horses. However, certain populations remain at increased risk.

Evidence Summary

Large retrospective studies have found no conclusive evidence of causal association between therapeutic systemic corticosteroid administration and laminitis development in healthy adult horses. However, there is weak evidence of association in horses with underlying endocrine disease or severe systemic illness.

High-Risk Populations for Corticosteroid Use

• Horses with previous laminitis history
• Equine Metabolic Syndrome (EMS)
• Pituitary Pars Intermedia Dysfunction (PPID/Cushing's)
• Obese horses with regional adiposity
• Ponies
• Horses receiving multiple corticosteroid doses

Other Corticosteroid Adverse Effects

5. Sedative and Tranquilizer Adverse Effects

Alpha-2 Agonists (Xylazine, Detomidine, Romifidine)

Alpha-2 agonists are the most commonly used sedatives in equine practice. They provide both sedation and analgesia but have significant physiologic effects that must be understood.

Adverse Effects of Alpha-2 Agonists

Contraindications for Alpha-2 Agonists

• Neonates: Cardiac output is heart rate dependent; bradycardia causes severe hypotension
• Pre-existing cardiac arrhythmias: Exacerbates AV blocks
• Pregnant mares: May induce labor; decreases fetal oxygen delivery
• IV sulfonamides concurrently: Detomidine specifically - risk of cardiac arrhythmias
• Colic patients requiring monitoring: Masks pain, decreases GI motility

Acepromazine

Acepromazine is a phenothiazine tranquilizer that blocks dopamine receptors. Key adverse effects include: severe hypotension (vasodilation without compensatory reflex), penile prolapse (prolonged exposure can cause paraphimosis and permanent damage), and paradoxical excitement (rare). It provides NO analgesia and animals can "break through" sedation if startled.

6. Oxytetracycline Toxicity

Oxytetracycline (OTC) is unique in equine medicine because it is used both as an antimicrobial and for treatment of flexural limb deformities in neonatal foals at high doses. The mechanism involves calcium chelation inhibiting myofibroblast contraction and matrix metalloproteinase inhibition.

Dose Comparison

Adverse Effects

• Cardiovascular collapse: Rapid IV administration causes hypotension due to calcium chelation; slow administration essential
• Acute renal failure: Particularly with high doses in neonates; associated with dehydration, endotoxemia
• Rhabdomyolysis: Recently reported with high-dose therapy for flexural deformities
• Tooth discoloration: Permanent yellowing in young animals
• Hyperthermia: In foals, especially in hot weather
• Tendon laxity: Desired effect for contracted tendons but may cause unwanted laxity in unaffected limbs

7. Prostaglandin Adverse Effects

Prostaglandin F2alpha (dinoprost) is used for estrus cycle manipulation, treatment of persistent corpus luteum, and pyometra. Adverse effects are common but typically transient and dose-dependent.

Clinical Signs of Prostaglandin Side Effects

Signs typically appear within 15-20 minutes and resolve within 1 hour: sweating (often profuse), colic-like pain and cramping, restlessness/pacing, tachycardia, tachypnea/panting, diarrhea, urination/defecation, hypothermia (transient decrease in body temperature), and rarely ataxia or weakness.

Important Considerations

• Cloprostenol (synthetic analogue): Causes fewer and less severe side effects than natural dinoprost
• Micro-dosing: Using 1/10th standard dose virtually eliminates side effects while maintaining efficacy
• Never administer IV: IM only; IV administration causes severe adverse effects
• Contraindicated in pregnant mares: Causes abortion
• Human safety warning: Pregnant women and asthmatics should not handle; absorbed through skin

8. Metronidazole Toxicity

Metronidazole is a nitroimidazole antibiotic used for anaerobic infections in horses. It is generally well-tolerated, but high doses or prolonged therapy can cause neurologic toxicity.

Clinical Signs of Toxicity

Neurologic signs typically appear after 7-12 days of treatment at high doses: ataxia, nystagmus, depression, anorexia, tremors, weakness. In severe cases (rare in horses): seizures. Signs may persist for days to weeks after discontinuation.

Management

• Discontinue metronidazole immediately
• Supportive care
• Signs typically resolve within 1-2 weeks of drug discontinuation

Memory Aids

"NSAID = No Safety Against Intestinal Damage"

N - Nephrotoxicity (renal papillary necrosis)

S - Stomach ulcers (EGUS)

A - Albumin loss (protein-losing enteropathy)

I - Intestinal damage (Right Dorsal Colitis)

D - Dehydration increases all risks

"MOX = More Obvious neurosiX"

Moxidectin is MOre toxic than ivermectin: Only 3x overdose causes toxicity (vs. 10x for ivermectin), 100x more lipophilic, 6x longer half-life (23 days vs. 4 days)

"GABA Agonists = AVOID GABApentin relatives"

In macrocyclic lactone toxicity, AVOID: Benzodiazepines (diazepam), Barbiturates (phenobarbital) - these are GABA agonists and worsen toxicity